Dyne Therapeutics, Inc.

NASDAQ:DYN

Biotechnology

Healthcare
$16.03 +1.97%

+$0.38 today

Market cap
$3.00B
Beta
1.08
P/E (TTM)
-7.2
EPS (TTM)
-$2.74
52W Low $8.06High $25.00

Volume 2.44M

Average 1.71M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$403.21M

FY 2025 · Annual

Investing Cash Flow

-$28.75M

FY 2025 · Annual

Financing Cash Flow

$890.31M

FY 2025 · Annual

+9.9% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(149.29M)(168.1M)(235.94M)(317.42M)(446.21M)
Depreciation & Amortization1.09M1.68M1.67M1.67M2.05M
Deferred Income Tax2.59M0000
Stock-Based Compensation17.54M15.18M19.97M45.86M45.85M
Change in Working Capital9.26M(5.38M)26.31M(19.49M)(3.4M)
Accounts Receivables00000
Inventory00000
Accounts Payables13.7M(1.24M)22.97M(8.96M)8.25M
Other Working Capital(4.45M)(4.14M)3.34M(10.54M)(11.65M)
Other Non-Cash Items(746K)2.97M(173K)(3M)(1.49M)
Operating Cash Flow(119.56M)(153.65M)(188.16M)(292.37M)(403.21M)
Capital Expenditures(3.62M)(3.07M)(729K)(2.38M)(1.92M)
Acquisitions (Net)8K34K000
Purchases of Investments(236.72M)(121.18M)(44.26M)(317.44M)(180.53M)
Sales of Investments102.45M211.45M128.3M115.71M172.46M
Other Investing Activities(8K)(34K)035K(18.76M)
Investing Cash Flow(137.89M)87.2M83.31M(204.08M)(28.75M)
Debt Repayment0000147.7M
Common Stock Issued157.24M36.86M52.37M773.05M742.61M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities584K529K1.95M36.84M0
Financing Cash Flow157.82M37.39M54.32M809.9M890.31M
Effect of Forex Changes00000
Net Change in Cash(99.63M)(29.05M)(50.53M)313.45M458.35M
Free Cash Flow(123.18M)(156.71M)(188.89M)(294.75M)(405.13M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$446.2M
+ D&A$2.0M
+ Stock-Based Comp$45.9M
+ Deferred Tax$0
- Working Capital-$3.4M
- Other Non-Cash-$1.5M
= Operating Cash Flow-$403.2M
- Capex-$1.9M
= Free Cash Flow-$405.1M

Analysis

FY2025 free cash flow is -$405.1M. FCF conversion is 90.8% of net income. Operating cash flow was -$403.2M, with capex of -$1.9M. The largest bridge item is Stock-Based Comp at $45.9M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 5, 2026
8-KCurrent reportNov 5, 2026
4Statement of changes in beneficial ownershipOct 22, 2026
4Statement of changes in beneficial ownershipOct 6, 2026
8-KCurrent reportSep 29, 2026

Does DYN generate free cash flow?

Dyne Therapeutics, Inc. (DYN) generated -$405.13M of free cash flow in fiscal 2025.

How much operating cash flow does DYN produce?

Operating cash flow was -$403.21M, before capital expenditures of $1.92M.